Author of

• 30780

  +

  P2.03 - Biology (ID 162)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Biology
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 30836

    +

    P2.03-54 - Imprinted Genes Predict Non-Small Cell Lung Cancer Prognosis (Now Available) (ID 1214)

    10:15 - 18:15  |  Author(s): Wenbin Huang
    • Abstract
    • Slides

    Background
    

    Lung cancer (LC) is the leading cause of cancer mortality worldwide, Significant numbers of stage I/II patients after curative surgery present with recurrent and progressive disease. It is critical to identify additional biomarkers to predict prognosis of early stage NSCLC. In carcinogenesis, epigenetic modifications on imprinted genes are changed and lead to biallelic (loss of imprinting, LOI) and multiallelic (copy number variation, CNV) expression. We present here an epigenetic panel involved in NSCLC prognosis.

    Method
    

    Retrospective study of 123 NSCLC cases with known 5-year survival status. Samples from diagnostic bronchoscopies are subjected to in-situ hybridization targeting non-coding regions to show the expression status of imprinted genes. Total expression (TE), LOI and CNV are counted manually. A statistical model is generated based on the expression status of a 3-imprinting gene epigenetic panel (DCN, PEG10 and SNRPN) to classify the cases. The 5-year survival is used as the only standard for good or poor prognosis.

    Result
    

    The NSCLS cases can be classified into 4 groups by epigenetic panel. In group A with high expression of DCN, 91.2% (31/34) had poor prognosis, including 8 stage I, 6 stage II, 9 stage III and 8 stage IV. In group B with low expression of DCN and high expression of both PEG10 and SNRPN, 75% (6/8) had poor prognosis. In group C with low expression of DCN and low expression of either or both of PEG10 and SNRPN, 39.5% (30/76) had poor prognosis. In group D with no expression of DCN, PEG10 or SNRPN, 100% (5/5) had good prognosis, even when metastatic and recurrent cases are found, their average survival is more than 8 years.

    Conclusion
    

    Imprinting Gene epigenetic panel may provide a quantitative assessment of NSCLC prognosis, and complement standard pathologic staging. This explains the poor prognosis of some early stage ca. The prognostic role may help select individual cases for adjuvant therapies. Further studies with expanded epigenetic panel and larger patient sets are planned to refine the classification algorithm, and identify potential predictive biomarkers for specific therapies to advance personalized lung cancer care.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.